Definitive Chemoradiotherapy for Vulvar Cancer

Area of Science:

• Oncology
• Radiation Oncology
• Gynecologic Oncology

Background:

• Vulvar cancer treatment often involves surgery, but definitive chemoradiation (CRT) is an option for unresectable cases.
• Evaluating clinical outcomes of CRT is crucial for optimizing treatment strategies.

Purpose of the Study:

• To assess the clinical outcomes, including survival and recurrence rates, following definitive chemoradiation (CRT) for vulvar cancer.
• To identify risk factors associated with survival and recurrence after CRT for vulvar cancer.

Main Methods:

• Retrospective analysis of 25 women with vulvar cancer treated with definitive CRT between 1994 and 2015.
• Kaplan-Meier method used to estimate 3-year overall survival (OS), freedom from local recurrence, and freedom from distant recurrence.
• Univariate Cox regression models analyzed risk factors; toxicities assessed using Common Terminology Criteria for Adverse Events v. 4.0.

Main Results:

• At 3 years, OS was 71%, freedom from local recurrence was 65%, and freedom from distant recurrence was 78%.
• Older age was significantly associated with decreased OS and increased local recurrence.
• High rates of late G3 skin toxicity (45%) and lymphedema (25%) were observed at 3 years.

Conclusions:

• Definitive CRT is an effective and generally well-tolerated treatment for advanced, unresectable vulvar cancer.
• Further research is needed to refine patient selection for nonsurgical management of vulvar cancer.